BioNexus Gene Lab (BGLC) Other Operating Expenses (2024 - 2026)

BioNexus Gene Lab has disclosed Other Operating Expenses across 3 years of filings, most recently posting $255230.0 for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $255230.0, down 0.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 8.01% YoY), and the FY2025 annual result was $1.4 million, up 11.34% from the prior year.
• Other Operating Expenses came in at $255230.0 for Q1 2026 at BioNexus Gene Lab, down from $679050.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $1.1 million in Q4 2024 to a low of -$1.3 million in Q1 2024.
• The 3-year median for Other Operating Expenses is $257440.0 (2025), against an average of $171832.4.
• Peak annual rise in Other Operating Expenses reached 138.95% in 2025, while the deepest fall reached 47.29% in 2025.
• BioNexus Gene Lab's Other Operating Expenses stood at $1.1 million in 2024, then tumbled by 35.4% to $679050.0 in 2025, then tumbled by 62.41% to $255230.0 in 2026.
• The last three Other Operating Expenses figures came in at $255230.0 (Q1 2026), $679050.0 (Q4 2025), and $281696.0 (Q3 2025), per Business Quant data.